Reports
Sale
Global Botulinum Toxin Market Size, Share, Trends, Forecast: By Product Type: Type A, Type B; By Application: Aesthetic, Therapeutic; By End User: Hospital, Specialty Centers, Dermatology Clinics, Others; Patent Analysis; Grants Analysis; Clinical Trials Analysis; Funding Analysis; Regional Analysis; Supplier Landscape; 2024-2032
Global Botulinum Toxin Market Outlook
The global botulinum toxin market size was USD 7.18 billion in 2023, driven by the rising demand for minimally invasive cosmetic procedures across the globe. The market share is anticipated to grow further at a CAGR of 9.3% to achieve a value of USD 15.99 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Application of Botulinum Toxin in the Cosmetics Industry to Bolster the Growth of the Botulinum Toxin Industry
Based on application, the cosmetics segment is likely to account for a significant share in the market. This can be attributed to the anti-aging properties of the product, along with its ability to enhance facial appearance. Botulinum toxin can treat the frown lines on the skin, crow’s feet lines, and glabellar lines. Over the forecast period, the growing awareness about the beneficial properties of the product is likely to propel its demand in various cosmetic applications.
Anticipated Surge in the Sales of Type A Botulinum Toxin to Augment the Market Growth
On the basis of type, the type A segment is likely to gain traction in the forecast period, owing to the aesthetic applications of the product. In addition, the downstream product of botulinum toxin, such as Botox, is gaining a significant popularity, and is likely to witness a surge in sales. This factor is expected to propel the segment growth in the forecast period.
North America Accounts for a Significant Share in the Botulinum Toxin Industry
The high disposable income, penetration of major cosmetic brands in the region, technological advancements, and the rising cases of glabellar lines in North America have been driving the regional market growth. Over the forecast period, the rising demand for the product in countries like the United States and Canada is likely to provide a further impetus to the market. Furthermore, the growing focus of consumers on aesthetics and physical appearance is likely to augment the market growth.
Botulinum Toxin: Industry Definition and Segmentation
Botulinum toxin is a neurotoxic protein produced by Clostridium botulinum, an anaerobic, gram-positive, spore-forming, rod-shaped bacterium that is commonly found in soil. It is a substance that is commonly used in cosmetic applications. It also plays a significant role in the management of various medical conditions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market is divided into:
- Type A
- Type B
On the basis of application, the industry is segmented into:
- Cosmetics
- Non-Cosmetics
While the cosmetics segment is further divided into glabellar lines, lateral canthal lines (crow's feet), and forehead lines, among others, the non-cosmetics segment is further categorised into dystonia, chronic migraine, ophthalmologic disorders, and others, based on type.
Based on end user, the market can be divided into:
- Hospitals
- Clinics
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Demand for Cosmetic Surgeries to Boost the Growth of the Botulinum Toxin Industry
The global botulinum toxin industry is being driven by the increasing demand for cosmetic surgeries and minimally invasive procedures across the globe. Botulinum toxin is a vital component for cosmetic non-invasive surgical procedures. Thus, the growing demand for the product in hospitals and clinics to carry out cosmetic surgeries is aiding the market growth. The market is expected to be augmented by the amendments in the reimbursements policies to cover botulinum injections. In addition, the therapeutic applications of the product for critical and chronic diseases are anticipated to further propel the market growth in the forecast period. Furthermore, the efforts made by people to look youthful and healthy, without any pain or concussions are likely to fuel the demand for botulinum toxin.
Key Industry Players in the Global Botulinum Toxin Market
The report gives a detailed analysis of the following key players in the global botulinum toxin market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Galderma SA
- Merz Pharma GmbH
- AbbVie Inc.
- Revance
- Hugel, Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Global Botulinum Toxin Market Overview
4.1 Global Botulinum Toxin Market Historical Value (2017-2023)
4.2 Global Botulinum Toxin Market Forecast Value (2024-2032)
5 Global Botulinum Toxin Market Landscape
5.1 Global Botulinum Toxin Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Botulinum Toxin Product Landscape
5.2.1 Analysis by Product Type
5.2.2 Analysis by End User
5.2.3 Analysis by Applications
6 Global Botulinum Toxin Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.3 Porter’s Five Forces Model
6.4 Key Demand Indicators
6.5 Key Price Indicators
6.6 Industry Events, Initiatives, and Trends
6.7 Value Chain Analysis
7 Global Botulinum Toxin Market Segmentation
7.1 Global Botulinum Toxin Market by Product Type
7.1.1 Market Overview
7.1.2 Type A
7.1.3 Type B
7.2 Global Botulinum Toxin Market by Application
7.2.1 Market Overview
7.2.2 Aesthetic
7.2.3 Therapeutic
7.3 Global Botulinum Toxin Market by End User
7.3.1 Market Overview
7.3.2 Hospital
7.3.3 Specialty Centers
7.3.4 Dermatology Clinics
7.3.5 Others
7.4 Global Botulinum Toxin Market by Region
7.4.1 Market Overview
7.4.2 North America
7.4.3 Europe
7.4.4 Asia Pacific
7.4.5 Latin America
7.4.6 Middle East and Africa
8 North America Botulinum Toxin Market
8.1 Market Share by Country
8.2 United States of America
8.3 Canada
9 Europe Botulinum Toxin Market
9.1 Market Share by Country
9.2 United Kingdom
9.3 Germany
9.4 France
9.5 Italy
9.6 Others
10 Asia Pacific Botulinum Toxin Market
10.1 Market Share by Country
10.2 China
10.3 Japan
10.4 India
10.5 ASEAN
10.6 Australia
10.7 Others
11 Latin America Botulinum Toxin Market
11.1 Market Share by Country
11.2 Brazil
11.3 Argentina
11.4 Mexico
11.5 Others
12 Middle East and Africa Botulinum Toxin Market
12.1 Market Share by Country
12.2 Saudi Arabia
12.3 United Arab Emirates
12.4 Nigeria
12.5 South Africa
12.6 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Regulatory Framework
18.1 Regulatory Overview
18.1.1 US FDA
18.1.2 EU EMA
18.1.3 INDIA CDSCO
18.1.4 JAPAN PMDA
18.1.5 Others
19 Supplier Landscape
19.1 F. Hoffmann-La Roche Ltd
19.1.1 Financial Analysis
19.1.2 Product Portfolio
19.1.3 Demographic Reach and Achievements
19.1.4 Mergers and Acquisitions
19.1.5 Certifications
19.2 GlaxoSmithKline plc
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Mergers and Acquisitions
19.2.5 Certifications
19.3 Medtronic
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Mergers and Acquisitions
19.3.5 Certifications
19.4 ALLERGAN
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Mergers and Acquisitions
19.4.5 Certifications
19.5 Pfizer Inc
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Mergers and Acquisitions
19.5.5 Certifications
19.6 Ipsen Pharma
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Mergers and Acquisitions
19.6.5 Certifications
19.7 UCB Pharma Ltd.
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Mergers and Acquisitions
19.7.5 Certifications
19.8 Sanofi
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Mergers and Acquisitions
19.8.5 Certifications
19.9 INMED PHARMACEUTICALS INC
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Mergers and Acquisitions
19.9.5 Certification
19.10 Orient Pharma
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Mergers and Acquisitions
19.10.5 Certifications
19.11 Taj Pharmaceuticals Limited
19.11.1 Financial Analysis
19.11.2 Product Portfolio
19.11.3 Demographic Reach and Achievements
19.11.4 Mergers and Acquisitions
19.11.5 Certifications
19.12 Johnson & Johnson Services, Inc
19.12.1 Financial Analysis
19.12.2 Product Portfolio
19.12.3 Demographic Reach and Achievements
19.12.4 Mergers and Acquisitions
19.12.5 Certifications
19.13 MediciNova, Inc.
19.13.1 Financial Analysis
19.13.2 Product Portfolio
19.13.3 Demographic Reach and Achievements
19.13.4 Mergers and Acquisitions
19.13.5 Certifications
19.14 Sun Pharmaceutical Industries Ltd
19.14.1 Financial Analysis
19.14.2 Product Portfolio
19.14.3 Demographic Reach and Achievements
19.14.4 Mergers and Acquisitions
19.14.5 Certifications
19.15 Novartis AG
19.15.1 Financial Analysis
19.15.2 Product Portfolio
19.15.3 Demographic Reach and Achievements
19.15.4 Mergers and Acquisitions
19.15.5 Certifications
19.16 Teva Pharmaceutical Industries Ltd
19.16.1 Financial Analysis
19.16.2 Product Portfolio
19.16.3 Demographic Reach and Achievements
19.16.4 Mergers and Acquisitions
19.16.5 Certifications
19.17 Merz Pharma
19.17.1 Financial Analysis
19.17.2 Product Portfolio
19.17.3 Demographic Reach and Achievements
19.17.4 Mergers and Acquisitions
19.17.5 Certifications
19.18 GW Pharmaceuticals plc
19.18.1 Financial Analysis
19.18.2 Product Portfolio
19.18.3 Demographic Reach and Achievements
19.18.4 Mergers and Acquisitions
19.18.5 Certifications
19.19 Revance Therapeutics
19.19.1 Financial Analysis
19.19.2 Product Portfolio
19.19.3 Demographic Reach and Achievements
19.19.4 Mergers and Acquisitions
19.19.5 Certifications
19.20 Acorda Therapeutics
19.20.1 Financial Analysis
19.20.2 Product Portfolio
19.20.3 Demographic Reach and Achievements
19.20.4 Mergers and Acquisitions
19.20.5 Certifications
20 Global Botulinum Toxin Market - Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global botulinum toxin market was valued at USD 7.18 billion in 2023.
The market is expected to grow at a CAGR of 9.3% during the forecast period of 2024-2032 to reach a value of USD 15.99 billion by 2032.
The growth of the market is driven by factors like rising demand for better appearance and the rising awareness about the importance of skincare.
The major regional markets can be categorized into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The product types in the market include Type A and B.
The product finds wide applications in aesthetic and therapeutic procedures.
The end-users of the product include hospitals, specialty centres, and dermatology clinics, among others.
The key players in the market include F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Medtronic, ALLERGAN, Pfizer Inc, Ipsen Pharma, UCB Pharma Ltd., Sanofi, INMED PHARMACEUTICALS INC, Orient Pharma, Taj Pharmaceuticals Limited, Johnson & Johnson Services, Inc, MediciNova, Inc., Sun Pharmaceutical Industries Ltd, Novartis AG, Teva Pharmaceutical Industries Ltd, Merz Pharma, GW Pharmaceuticals plc, Revance Therapeutics, and Acorda Therapeutics.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER